Monitoring and Evaluation of MDR TB Kęstutis Miškinis, Medical officer, WHO Ukrainian country office.

Slides:



Advertisements
Similar presentations
ISTC Training Modules 2008 Your name Institution/organization Meeting Date.
Advertisements

DOTS/ DOTS PLUS IMPLEMENTATION AND INTEGRATION Vaira Leimane State Centre of Tuberculosis and Lung Diseases of Latvia Paris, October, 28.
Improving diagnosis TB laboratory strengthening.
Introduction India has the highest burden of tuberculosis in the world, with an estimated 2 million cases annually, accounting for 1/5 th of global incidence.
1 [INSERT COUNTRY NAME HERE] Introduction to the National MDR-TB Control Strategy SESSION 1 Insert country/ministry logo here.
Overview of current case and treatment outcome definitions Malgosia Grzemska TB Operations and Coordination Stop TB Department Consultation Impact of WHO-endorsed.
World Health Organization TB Case Definitions
1 Identifying Cases of MDR-TB Session 3. USAID TB CARE II PROJECT Old WHO recommendations RegimenIndications 4HREZ/2HR (Category I) New cases 2SHREZ/1HREZ/5HRE.
Development of extensive drug resistance in Multi-Drug resistant tuberculosis patients MSF anti-TB programmes in Abkhazia and Uzbekistan Authors: Cathy.
Multi-drug Resistant Tuberculosis Hail M. Al-Abdely Consultant, Infectious Diseases, KFSH&RC.
World Tuberculosis Day 2015 The TB situation in 2013: Findings from the joint TB surveillance and monitoring report by ECDC and the WHO Regional Office.
Role of the laboratory in disease surveillance
Module 3: Drug-Resistant TB. Learning Objectives Describe how drug resistance emerges Explain the difference between primary and secondary resistance.
Second Line Drugs Susceptibility Testing: Study Progress Report Alex Sloutsky Massachusetts State TB Laboratory Paris, 2005.
Monitoring and Evaluation: Tuberculosis Control Programs
HIV-TB Model: The Botswana experience By E.M. Lungu (UB) M. Kgosimore (BCA) F. Nyabadza (UB) Modeling Disease in Africa Workshop 25 – 27 June 2007, Stellenbosch,
COUNTRY XEPERIENCE AND RESPONSE TO MDR AND XDR TUBERCULOSIS PRESENTED AT THE WHO TB/HIV PLANNING MEETING, ADDIS ABBABA, 11-12, NOVEMBER 2008 BY MS GUGU.
World Tuberculosis Day 2014 The TB situation in 2012: Findings from the joint TB surveillance and monitoring report by ECDC and the WHO Regional Office.
World Tuberculosis Day 2014 The TB situation in 2012: Findings from the joint TB surveillance and monitoring report by ECDC and the WHO Regional Office.
MDR and XDR TB Bruce A. Bush, M.D. Regional Tuberculosis Consultant
Tuberculosis in the UK 2013 report
1 Introduction to Drug-Resistant TB Session 2. USAID TB CARE II PROJECT Classification of drug-resistant TB “Drug-resistant TB” is a general term to describe.
4 th National Anti-tuberculosis Drug Resistance Survey Botswana, 2007.
The Global Plan to Stop TB, (1)
MDR-TB: a fight we cannot afford to lose! Alexander Golubkov, MD, MPH Senior TB Technical Advisor.
RNTCP: DOTS Expansion and plans for DOTS-Plus
World Health Organization
Multi-drug resistant tuberculosis: Progress and challenges in South Africa Dr S. Moyo HIV/AIDS, Sexually Transmitted Infections and TB research (HAST)Programme.
Three key messages on tuberculosis control World Tuberculosis Day 2010 ECDC TB Team European Centre for Disease Prevention and Control Stockholm, 24 March.
Monitoring and Evaluation Module 12 – March 2010.
Tuberculosis Research of INA-RESPOND on Drug-resistant
1 Module OVERVIEW OF EXTERNAL QUALITY ASSESSMENT.
Monitoring Drug Resistant Tuberculosis Treatment in Brazil through an Innovative Web-based Information System Dr. Luis Gustavo Bastos Management Sciences.
Thank you for viewing this presentation. We would like to remind you that this material is the property of the author. It is provided to you by the ERS.
World Health Assembly 63 Geneva, Suisse May 2010 WORLD HEALTH EDITORS NETWORK Tracking Global Health News: building health literacy Multi-Drug Resistant.
Tuberculosis in the United States National Tuberculosis Surveillance System Highlights from 2011 National Center for HIV/AIDS, Viral Hepatitis, STD, and.
1 Oct 2005 WHO/STB/THD World Health Organization 4 th Meeting of Subgroup on laboratory capacity strengthening Paris, France, October Ernesto Jaramillo.
PREVALENCE OF MDR-TB AMONGST PATIENTS WITH HIV AND TB CO- INFECTION SEEN AT THE DOTS CLINIC OF N.I.M.R., LAGOS, NIGERIA. Enya V.N.V, Onubogu C.C., Wahab.
DOTS-PLUS IN TANZANIA: PREPARATION PHASE Global DOTS Expansion Working Group Meeting, Paris: 28 October 2004 NTLP - MOH Prepared by: Dr. S. M. Egwaga NTLP.
Treating MDR-TB A Challenge Throughout ECA Public Health Practice II.
International Health Policy Program -Thailand Policy decision on multi drug resistant(MDR), extreme drug resistant(XDR) tuberculosis screening: How it.
PMDT expansion is first of all expansion of DR-TB detection services Workshop on the development and implementation of supervision and patient support.
Health Organization The Challenges Facing Tuberculosis Control Blantyre Hospital, Malawi: TB Division, 3 patients per bed.
Public Health. TB-DOTS program Government commitment Case detection by DSSM among symptomatic patients self-reporting to health services Standard short-course.
TB Management: A Medical Aid Perspective presented by Dr Noluthando Nematswerani.
Unit 11 Drug Resistance and MDR-TB: B Family Case Botswana National Tuberculosis Programme Manual Training for Medical Officers.
By: Mpho Kontle and Topo Moses. Introduction & Etiology Multi-drug-resistant tuberculosis (MDR-TB) is defined as tuberculosis that is resistant to at.
Measures to Decrease TB Prevalence in the Barents Region Andrey O. Maryandyshev Elena I. Nikishova Dmitry V. Perkhin.
Peter Cegielski, MD, MPH Team Leader for Prevention, Care and Treatment Global Tuberculosis Branch Division of Global HIV and TB Reinforcing the Surveillance.
PMDT IN CHINESE TAIPEI ECONOMY Anita Pei-Chun Chan, MD, PhD Medical Officer, TCDC Associated Director, TB Research Center, TCDC Assistant Professor, Institute.
Compendium of Indicators for Monitoring and Evaluating National Tuberculosis Programs.
World Tuberculosis Day 2016 Monitoring the implementation of the Framework Action Plan to Fight Tuberculosis in the European Union – Situation in 2014.
Comprehensive Treatment of Extensively Drug-Resistant Tuberculosis N Engl J Med 2008;359: R2 이 설 라.
Taipei, June Content  Introduction about Vietnam’s Programmatic Management of Drug resistant Tuberculosis (PMDT) and drug resistant tuberculosis.
TB- HIV Collaborative activities in Romania- may 2006 status
Treatment of TB Disease
World Tuberculosis Day 2014
World Tuberculosis Day 2014
World Tuberculosis Day 2015
Monitoring the implementation of the TB Action Plan for the WHO European Region, 2016–2020 EU/EEA situation in 2016 ECDC Tuberculosis Programme European.
XDR TUBERCULOSIS IN EUROPE EPIDEMIOLOGICAL ASPECTS
Knowledge gaps in formulating TB Control Policies for Prisons
World Tuberculosis Day 2014
Richard Laing, Kelly McGoldrick
World Tuberculosis Day 2016
World Tuberculosis Day 2014
Tuberculosis in Wales Annual Report 2018 Data to the end of 2017
5th DEWG meeting Conclusions
monitoring & evaluation THD Unit, Stop TB department WHO Geneva
Tuberculosis in Wales Annual Report 2017 Data to the end of 2016
Presentation transcript:

Monitoring and Evaluation of MDR TB Kęstutis Miškinis, Medical officer, WHO Ukrainian country office

What is multidrug-resistant tuberculosis (MDR-TB)? TB bacilli resistant to at least two of the most powerful anti-TB agents: isoniazid and rifampicin; One of the main aims of any national TB program is to minimize the development of drug (multidrug) resistance;

Effectiveness of National TB Programme High cure rate of new TB cases; Low (and constantly decreasing) MDR-TB rate; Ultimately, high case-detection rate; Potential criteria: Ability to analyze cohort data; Default and transfer rates less than 10%; Continual supply of 1st line anti-TB drugs; Application of DOT in 90% of all cases;

Effectiveness of National TB Programme (con’t.) Surveillance of anti-TB drug resistance is an essential tool for monitoring the effectivness of TB control programme in any country; The use of drug-sensitivity tests (DST) was recommended many years ago;

Cause of anti-TB drug resistance (M)DR-TB is man-made! Naturally drug- resistant organisms arising through spontaneous mutations are selected by inadequate drug regimens; Reasons – exposure to a single drug due to: Poor adherence; Inappropriate prescription; Irregular drug supply; Poor drug quality;

MDR-TB Problems: longer to treat (up to 24 months); more expensive (up to 100x); more side-effects; demanding follow-up mechanism; requires complex diagnostics;

Prevalence of (M)DR-TB in some regions WHO / IUATLD / DZK / AKM % 20% 40% 60% 80% 100% Germany Italy Israel Latvia Tomsk Oblast Ivanovo Oblast China Henan Estonia resistantMDR TB susceptible

Countries/settings with MDR rates higher than 10% among combined cases

Boxplots of MDR prevalence rates among New Cases by European Sub-regions 3rd Global Report of WHO

MDR Trends among New Cases in Lithuania and Estonia Confidence-bounded MDR trend among new patients in Estonia Confidence-bounded MDR trend among new patients in Lithuania

Establishment of drug-resistance surveillance system The sample of specimens should be representative of the TB patients; The patient’s history should be carefully obtained (available to determine whether the patient has previously received anti- TB drugs); The laboratory methods should meet internationally recommended standards;

DST methods Proportion; Resistance ratio; Absolute concentration; BACTEC 460 radiometric; Comparability of data is assured by: Quality assurance; Proficiency testing performed by Supranational Reference Laboratories

Choice of drugs Four out of six 1st line drugs: Isoniazid (H);Isoniazid (H); Rifampicin (R);Rifampicin (R); Streptomycin (S);Streptomycin (S); Ethambutol (E);Ethambutol (E); Why these four? Widely used;Widely used; Resistance can be reliably measured by standardized techniques;Resistance can be reliably measured by standardized techniques;

Definitions of resistance Resistance among previously treated cases (having been treated for tuberculosis for one month or more);Resistance among previously treated cases (having been treated for tuberculosis for one month or more); Resistance among new TB cases (denies having had prior anti-TB treatment);Resistance among new TB cases (denies having had prior anti-TB treatment); Multi-drug resistance;Multi-drug resistance;

National Reference Laboratory Is a reference institution on MDR surveillance. It: Prepares cultures;Prepares cultures; Undertakes identification of Mycobacteria;Undertakes identification of Mycobacteria; Undertakes DST;Undertakes DST; Ensures quality of DST performed by regional labs;Ensures quality of DST performed by regional labs; Establishes a regular “on-site” supervision;Establishes a regular “on-site” supervision;

Organizing of surveillance Laboratories and diagnostic centers;Laboratories and diagnostic centers; Sample size and sampling strategies;Sample size and sampling strategies; Organization and survey outline (preparation, sampling, training, logistics);Organization and survey outline (preparation, sampling, training, logistics); Intake of patients (inclusion criteria, sputum-collection, registration, transport);Intake of patients (inclusion criteria, sputum-collection, registration, transport); National Reference laboratory;National Reference laboratory; Data management and analysis;Data management and analysis;

Ukraine NRL is established, but not functioning; QA is not implemented; Proficiency testing hasn’t started yet; Laboratory standards are defined, but not strictly followed; Equipment is poor, purchase of new equipment and necessary supplies is often delayed; Staff needs retraining and rejuvenation;

Trends in Anti-TB-Drug- Resistance in Ukraine Feshchenko et al., Ukraine Chemotherapeutical Journal, 2000/3 YearNo of Isolates Number of stains % Number of strains % testedsusceptible with resistance(s) ,534846, ,438047, ,140247, ,851749, ,837549, ,342151, ,237850, ,137250, ,152554, ,758961,3

Year Drug resistance (%) Monodrug resistance Multidrug resistance MDR Polydrug resistance Trends in Anti-TB-Drug- Resistance in Ukraine Feshchenko et al., Ukraine Chemotherapeutical Journal, 2000/3

Civil sectorPenitentiary system Total newPrev trNewPrev trNewPrev tr Susceptible strains abs% % % % % % Resistant strains MDR MDR survey results in Donetska oblast ( )

Drug Resistance Surveillance Magnitude and trend of drug resistance prevalence among new and re-treatment cases; Useful parameter to evaluate current and past treatment programme; Useful information for selection of effective initial treatment and retreatment regimens;

Should we treat persons with MDR-TB? Yes…for humanitarian reasons But health policy is not only driven by values, facts also matter No... unless it is proven that it is feasible and cost-effective But can we afford not to respond?

DOTS-Plus: working definition DOTS-Plus is a case-management strategy under development designed to manage MDR-TB using 2nd line drugs within the DOTS strategy in low- and middle-income countries; DISCLAIMER: DOTS-Plus means DOTS first

Prevention of MDR TB Correct operations of the TB programme: Diagnosis based on bacteriological examination; Standard treatment under strict observation (DOT); Uninterrupted supply of good-quality TB drugs (recommended FDC); Proper recording and reporting;